Results 201 to 210 of about 1,609,187 (354)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction. [PDF]

Nat Commun, 2023
Sülzen H, Began J, Dhillon A, Kereïche S, Pompach P, Votrubova J, Zahedifard F, Šubrtova A, Šafner M, Hubalek M, Thompson M, Zoltner M, Zoll S.   +12 more
europepmc   +1 more source

The Ability of Smooth and Rough Strains of Streptococcus Pneumoniae to Activate Human Complement by the Alternative Pathway

, 1978
M S Edwards, J. M. Stark
openalex   +1 more source

Effect of membrane phospholipids on activation of the alternative complement pathway. [PDF]

, 1989
Carolyn Mold
openalex   +1 more source

Decrypting cancer's spatial code: from single cells to tissue niches

Molecular Oncology, EarlyView.
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik, Shi Pan, Eloise Withnell, Hou Wang Lam, Maria Secrier   +4 more
wiley   +1 more source

Chronic kidney disease enhances alternative pathway activity: a new paradigm. [PDF]

J Clin Invest
Jalal DI, Thurman JM, Smith RJ.
europepmc   +1 more source

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19. [PDF]

Immunology, 2023
Siggins MK, Davies K, Fellows R, Thwaites RS, Baillie JK, Semple MG, Openshaw PJM, Zelek WM, Harris CL, Morgan BP, ISARIC4C Investigators.   +10 more
europepmc   +1 more source

Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. [PDF]

, 1984
James T. Mayes, Robert D. Schreiber, Neil R. Cooper   +2 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

AAPM Task Group 298: Recommendations on certificate program/alternative pathway candidate education and training. [PDF]

J Appl Clin Med Phys, 2022
Prisciandaro JI, Burmeister JW, DeLuca PM, Gerbi BJ, Giger ML, Robar JL, Seibert JA.   +6 more
europepmc   +1 more source